Working… Menu

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04176991
Recruitment Status : Completed
First Posted : November 26, 2019
Last Update Posted : November 12, 2020
Veristat, Inc.
Metrum Research Group, LLC
Information provided by (Responsible Party):
Larimar Therapeutics, Inc.